Enalapril: Research, Dosing, and Where to Buy in 2026
A research-first profile for Enalapril (nalopril), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Enalapril is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, 4 attributed expert mentions, and 2 transcript dosing protocols for Enalapril, each linked to its source.
- Also indexed as nalopril.
- 2 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Enalapril?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 1 cited mention
"2.5 mg enalapril, start there or 40 mg telmisartan... If your blood pressure is not in range, then I would look into 2.5 mg to 5 mg enalapril. That will bring your hematocrit down really really fast."
Enalapril Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | Oral Vs Injectable SLU-PP-332, Ideal GH To Test Ratio, High... | 01:01:00 | 2.5-5 mg enalapril/day brings hematocrit down quickly. More potent than 40 mg telmisartan for hematocrit reduction. | anecdotal |
| Vigorous Steve | These Compound Are Ruining Your Endurance, What You Need To Avoid... | 00:03:56 | 2.5 mg to 10 mg daily lowers hematocrit and red blood cell count; avoid for endurance | anecdotal |
Where to Buy Enalapril in 2026
No tracked vendor recommendations for Enalapril yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Enalapril. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“2.5 mg enalapril, start there or 40 mg telmisartan... If your blood pressure is not in range, then I would look into 2.5 mg to 5 mg enalapril. That will bring your hematocrit down really really fast.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Enalapril. Each line links to the original source.
- "Cough was reported in <or=5.2% and peripheral oedema in <or=1.5% of lercanidipine/enalapril recipients." · Hair P et al, 2007 PubMed
- "Of 209 patients taking enalapril, 22 (10.5%) required discontinuation of therapy because of an intractable, dry cough." · Gibson G et al, 1989 PubMed
- "Cough was more than twice as common in women; 16 (14.6%) of 109 women and 6 (6%) of 100 men stopped taking enalapril because of cough." · Gibson G et al, 1989 PubMed
- "Optimal clinical application of enalapril in the treatment of hypertension and congestive heart failure will require increased awareness of this incessant cough, which requires discontinuation of the therapy in about 10% of patients." · Gibson G et al, 1989 PubMed
- "The crude mortality at the end of six months (primary end point) was 26 percent in the enalapril group and 44 percent in the placebo group--a reduction of 40 percent (P = 0.002)." · [] et al, 1987 PubMed
- "Mortality was reduced by 31 percent at one year (P = 0.001)." · [] et al, 1987 PubMed
- "By the end of the study, there had been 68 deaths in the placebo group and 50 in the enalapril group--a reduction of 27 percent (P = 0.003)." · [] et al, 1987 PubMed
- "The entire reduction in total mortality was found to be among patients with progressive heart failure (a reduction of 50 percent), whereas no difference was seen in the incidence of sudden cardiac death." · [] et al, 1987 PubMed
- "Enalapril maleate is a prodrug which is quickly absorbed, hydrolyzed by the liver to the active metabolite enalaprilic acid, and excreted 33 percent in the bile and 61 percent in the urine." · Cleary J et al, 1986 PubMed
Research and Studies
8 PubMed-indexed papers reference Enalapril. Top 8 shown.
Legal Status
Enalapril is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Enalapril FDA-approved?
Enalapril is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Enalapril?
This page aggregates 2 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Enalapril?
8 PubMed-indexed paper(s) reference Enalapril in our current research feed. See the Research and Studies section above for citations.